The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Treatment of Hepatitis C: A Systematic Review
Abstract
IMPORTANCE: Hepatitis C virus (HCV) infects more than 185 million individuals worldwide. Twenty percent of patients chronically infected with HCV progress to cirrhosis. New, simpler therapeutics using direct-acting antivirals that target various stages of the HCV life cycle are in development to eradicate HCV without concomitant interferon. OBJECTIVES: To summarize published evidence on safety, efficacy (measured by a sustained virologic response [SVR], which is the treatment goal of undetectable plasma HCV RNA 12 or 24 weeks after therapy completion), and tolerability of current US Food and Drug Administration-approved interferon-based regimens and oral interferon-free regimens used for treating HCV infection and coinfection with human immunodeficiency virus (HIV) and HCV; to provide treatment recommendations for specialists and generalists based on published evidence. EVIDENCE REVIEW: A literature search of Web of Science, Scopus, Embase, Agricola, Cochrane Library, Cinahl Plus, ClinicalTrials.gov, Conference Papers Index, Gideon, PsycINFO, Google Scholar, and Oaister was conducted from January 1, 2009, to May 30, 2014. Publications describing phase 2, 3, and 4 studies evaluating the treatment of HCV were included. Forty-one studies involving 19,063 adult patients were included. Strength of clinical data and subsequent HCV treatment recommendations were graded according to the Oxford Centre for Evidence-Based Medicine. FINDINGS: Patients infected with HCV genotype 1 represent 60% to 75% of HCV infections in the United States. Hepatitis C virus genotype 1 is more difficult to cure than genotype 2 or genotype 3. Patients with HCV genotype 1 should receive treatment with sofosbuvir + pegylated interferon + ribavirin because of the shorter duration of therapy and high rates of SVR (89%-90%). Simeprevir + pegylated interferon + ribavirin is an alternative for patients with HCV genotype 1 (SVR, 79%-86%). Patients with HCV genotypes 2 and 3, representing 20% to 29% of US HCV infections, should receive therapy with sofosbuvir + ribavirin alone (SVR for genotype 2, 12 weeks' duration: 82%-93%; SVR for genotype 3, 24 weeks' duration, 80%-95%). Patients with HIV-HCV coinfection and patients with compensated cirrhosis (ie, cirrhosis but preserved synthetic liver function) should receive the same treatment as HCV-monoinfected patients. CONCLUSIONS AND RELEVANCE: New, short-duration, simpler therapies result in high SVR rates for HCV-infected patients. In conjunction with increased screening for HCV as suggested by recent Centers for Disease Control and Prevention guidelines, availability of new therapies may lead to the treatment of many more people with chronic HCV infection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., & Altman, D. G. (2009) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2009.06.005 · Cited by 19,575
Isolation of a cDNA cLone Derived from a Blood-Borne Non-A, Non-B Viral Hepatitis Genome
Choo, Q.-L., Kuo, G., Weiner, A. J., Overby, L. R., Bradley, D. W., & Houghton, M. (1989) · Science · doi:10.1126/science.2523562 · Cited by 6,875
McHutchison, J. G., Gordon, S. C., Schiff, E. R., Shiffman, M. L., Lee, W. M., Rustgi, V. K., Goodman, Z. D., Ling, M.-H., Cort, S., & Albrecht, J. K. (1998) · New England Journal of Medicine · doi:10.1056/nejm199811193392101 · Cited by 3,465
Boceprevir for Untreated Chronic HCV Genotype 1 Infection
Poordad, F., McCone, J., Bacon, B. R., Bruno, S., Manns, M. P., Sulkowski, M. S., Jacobson, I. M., Reddy, K. R., Goodman, Z. D., Boparai, N., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1010494 · Cited by 2,520
Mohd Hanafiah, K., Groeger, J., Flaxman, A. D., & Wiersma, S. T. (2013) · Hepatology · doi:10.1002/hep.26141 · Cited by 2,515
Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection
Jacobson, I. M., McHutchison, J. G., Dusheiko, G., Di Bisceglie, A. M., Reddy, K. R., Bzowej, N. H., Marcellin, P., Muir, A. J., Ferenci, P., Flisiak, R., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1012912 · Cited by 2,398
Poynard, T., Marcellin, P., Lee, S. S., Niederau, C., Minuk, G. S., Ideo, G., Bain, V., Heathcote, J., Zeuzem, S., Trepo, C., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(98)07124-4 · Cited by 2,318
Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
Lawitz, E., Mangia, A., Wyles, D., Rodriguez-Torres, M., Hassanein, T., Gordon, S. C., Schultz, M., Davis, M. N., Kayali, Z., Reddy, K. R., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1214853 · Cited by 1,788
Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection
Afdhal, N., Zeuzem, S., Kwo, P., Chojkier, M., Gitlin, N., Puoti, M., Romero-Gomez, M., Zarski, J.-P., Agarwal, K., Buggisch, P., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402454 · Cited by 1,705
Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection
Bacon, B. R., Gordon, S. C., Lawitz, E., Marcellin, P., Vierling, J. M., Zeuzem, S., Poordad, F., Goodman, Z. D., Sings, H. L., Boparai, N., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009482 · Cited by 1,626
Telaprevir for Retreatment of HCV Infection
Zeuzem, S., Andreone, P., Pol, S., Lawitz, E., Diago, M., Roberts, S., Focaccia, R., Younossi, Z., Foster, G. R., Horban, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1013086 · Cited by 1,546
Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options
Jacobson, I. M., Gordon, S. C., Kowdley, K. V., Yoshida, E. M., Rodriguez-Torres, M., Sulkowski, M. S., Shiffman, M. L., Lawitz, E., Everson, G., Bennett, M., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1214854 · Cited by 1,090
Telaprevir with Peginterferon and Ribavirin for Chronic HCV Genotype 1 Infection
McHutchison, J. G., Everson, G. T., Gordon, S. C., Jacobson, I. M., Sulkowski, M., Kauffman, R., McNair, L., Alam, J., & Muir, A. J. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0806104 · Cited by 1,089
Ghany, M. G., Nelson, D. R., Strader, D. B., Thomas, D. L., & Seeff, L. B. (2011) · Hepatology · doi:10.1002/hep.24641 · Cited by 1,076
Telaprevir and Peginterferon with or without Ribavirin for Chronic HCV Infection
Hézode, C., Forestier, N., Dusheiko, G., Ferenci, P., Pol, S., Goeser, T., Bronowicki, J.-P., Bourlière, M., Gharakhanian, S., Bengtsson, L., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0807650 · Cited by 1,025
Smith, B. D., Morgan, R. L., Beckett, G. A., Falck-Ytter, Y. T., Holtzman, D. J., Teo, C., Jewett, A., Baack, B. N., Rein, D. B., Patel, N., et al. (2012) · PubMed · Cited by 991
Treatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin
Feld, J. J., Kowdley, K. V., Coakley, E., Sigal, S., Nelson, D. R., Crawford, D., Weiland, O., Aguilar, H., Xiong, J., Pilot-Matias, T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1315722 · Cited by 903
Davis, G. L., Alter, M. J., El–Serag, H., Poynard, T., & Jennings, L. W. (2010) · Gastroenterology · doi:10.1053/j.gastro.2009.09.067 · Cited by 878
Nucleotide Polymerase Inhibitor Sofosbuvir plus Ribavirin for Hepatitis C
Gane, E. J., Stedman, C. A., Hyland, R. H., Ding, X., Svarovskaia, E., Symonds, W. T., Hindes, R. G., & Berrey, M. M. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1208953 · Cited by 764
Response-Guided Telaprevir Combination Treatment for Hepatitis C Virus Infection
Sherman, K. E., Flamm, S. L., Afdhal, N. H., Nelson, D. R., Sulkowski, M. S., Everson, G. T., Fried, M. W., Adler, M., Reesink, H. W., Martin, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014463 · Cited by 750
Sherman, K. E., Rouster, S. D., Chung, R. T., & Rajicic, N. (2002) · Clinical Infectious Diseases · doi:10.1086/339042 · Cited by 733
Kwo, P. Y., Lawitz, E. J., McCone, J., Schiff, E. R., Vierling, J. M., Pound, D., Davis, M. N., Galati, J. S., Gordon, S. C., Ravendhran, N., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60934-8 · Cited by 704
Estimating progression to cirrhosis in chronic hepatitis C virus infection
Freeman, A. J., Dore, G. J., Law, M. G., Thorpe, M., Von Overbeck, J., Lloyd, A. R., Marinos, G., & Kaldor, J. M. (2001) · Hepatology · doi:10.1053/jhep.2001.27831 · Cited by 620
Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3
Rubbia-Brandt, L., Quadri, R., Abid, K., Giostra, E., Malé, P.-J., Mentha, G., Spahr, L., Zarski, J.-P., Borisch, B., Hadengue, A., et al. (2000) · Journal of Hepatology · doi:10.1016/s0168-8278(00)80166-x · Cited by 593
Hepatitis C virus infection in USA: an estimate of true prevalence
Chak, E., Talal, A. H., Sherman, K. E., Schiff, E. R., & Saab, S. (2011) · Liver International · doi:10.1111/j.1478-3231.2011.02494.x · Cited by 396
Swain, M. G., Lai, M., Shiffman, M. L., Cooksley, W. G. E., Zeuzem, S., Dieterich, D. T., Abergel, A., Pessôa, M. G., Lin, A., Tietz, A., et al. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.07.009 · Cited by 328
Osinusi, A., Meissner, E. G., Lee, Y.-J., Bon, D., Heytens, L., Nelson, A., Sneller, M., Kohli, A., Barrett, L., Proschan, M., et al. (2013) · JAMA · doi:10.1001/jama.2013.109309 · Cited by 291
Self-citationFried, M. W., Buti, M., Dore, G. J., Flisiak, R., Ferenci, P., Jacobson, I., Marcellin, P., Manns, M., Nikitin, I., Poordad, F., et al. (2013) · Hepatology · doi:10.1002/hep.26641 · Cited by 272
Raimondi, S., Bruno, S., Mondelli, M. U., & Maisonneuve, P. (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.01.019 · Cited by 224
Sulkowski, M. S., Sherman, K. E., Dieterich, D. T., Bsharat, M., Mahnke, L., Rockstroh, J. K., Gharakhanian, S., McCallister, S., Henshaw, J., Girard, P.-M., et al. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-159-2-201307160-00654 · Cited by 201
Peginterferon Alfa-2a and Ribavirin in Latino and Non-Latino Whites with Hepatitis C
Rodriguez-Torres, M., Jeffers, L. J., Sheikh, M. Y., Rossaro, L., Ankoma-Sey, V., Hamzeh, F. M., & Martin, P. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805062 · Cited by 180
Drug–drug interactions during antiviral therapy for chronic hepatitis C
Kiser, J. J., Burton, J. R., & Everson, G. T. (2013) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2013.106 · Cited by 134
HIV, hepatitis C and HIV/hepatitis C virus co-infection in vulnerable populations
Backus, L. I., Boothroyd, D. B., & Deyton, L. (2005) · AIDS · doi:10.1097/01.aids.0000192065.09281.01 · Cited by 78
Wilby, K. J., Greanya, E. D., Ford, J., Yoshida, E. M., & Partovi, N. (2012) · Annals of Hepatology · doi:10.1016/s1665-2681(19)31022-1 · Cited by 78
Vachon, M.-L., Factor, S. H., Branch, A. D., et al. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2010.06.025 · Cited by 21
Cited by
Siegel, R. L., Miller, K. D., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21442 · Cited by 16,579
Mehra, M. R., Canter, C. E., Hannan, M. M., Semigran, M. J., Uber, P. A., Baran, D. A., Danziger-Isakov, L., Kirklin, J. K., Kirk, R., Kushwaha, S. S., et al. (2016) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2015.10.023 · Cited by 1,431
Global cancer in women: burden and trends.
Torre, L. A., Islami, F., Siegel, R. L., Ward, E. M., & Jemal, A. (2017) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-16-0858 · Cited by 1,245
Zeuzem, S., Ghalib, R., Reddy, K. R., Pockros, P. J., Ari, Z. B., Zhao, Y., Brown, D. D., Wan, S., DiNubile, M. J., Nguyen, B.-Y., et al. (2015) · Annals of Internal Medicine · doi:10.7326/m15-0785 · Cited by 516
Cancer statistics for Hispanics/Latinos, 2015
Siegel, R. L., Fedewa, S. A., Miller, K. D., Goding‐Sauer, A., Pinheiro, P. S., Martinez‐Tyson, D., & Jemal, A. (2015) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21314 · Cited by 468
Metadata
- Authors
- Kohli, A., Shaffer, A., Sherman, A., & Kottilil, S.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2014-08-13
- Volume
- 312
- Issue
- 6
- Pages
- 631
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2139252405
- Cited by
- 426
- References
- 37
- FWCI
- 36.14
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.